Phase II Evaluation of Dasatinib in the Treatment of Recurrent or Persistent Epithelial Ovarian or Primary Peritoneal Carcinoma: A Gynecologic Oncology Group Study
Gynecologic Oncology - United States
doi 10.1016/j.ygyno.2012.06.009
Full Text
Open PDFAbstract
Available in full text
Date
October 1, 2012
Authors
Publisher
Elsevier BV